Status:
UNKNOWN
The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients
Lead Sponsor:
IRCCS National Neurological Institute "C. Mondino" Foundation
Conditions:
Multiple Sclerosis Relapse
Eligibility:
All Genders
18-60 years
Brief Summary
Ocrelizumab (OCR) is a humanized anti-CD20 antibody approved for Relapsing Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS), due to neuroprotective effects of partially unkno...
Detailed Description
Ocrelizumab (OCR) is a humanized monoclonal anti-CD20 antibody approved by the FDA in 2017 and by the European Medicines Agency in 2018 for treatment of adult patients with Relapsing Multiple Sclerosi...
Eligibility Criteria
Inclusion
- Inclusion criteria
- The participant must have a previous diagnosis of RMS in accordance with the 2017 revised McDonald criteria
- The participant must have been newly prescribed to OCR treatment according to clinical practice
- Absence of high dose of steroid treatment for at least 4 weeks
- The participant must be capable of giving signed informed consent.
- Exclusion criteria
- Clinical MS relapse within four-week period prior to inclusion
- Pregnant or nursing (lactating) women.
- Chronic disease of the immune system, other than MS
- Active systemic bacterial, viral or fungal infections
- Allergy to OCR
- Already included in other interventional trials
Exclusion
Key Trial Info
Start Date :
May 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04902690
Start Date
May 31 2021
End Date
July 31 2024
Last Update
May 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.